Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Regeneron Pharmaceuticals, Inc. (REGN) had Free Cash Flow per Share of $13.41 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$4.29B |
|
$1.30B |
|
$576.50M |
|
$3.71B |
|
$3.00B |
|
$1.29B |
|
$234.30M |
|
$1.53B |
|
$1.53B |
|
$1.30B |
|
$1.30B |
|
$1.30B |
|
$1.30B |
|
$1.29B |
|
$1.42B |
|
102.80M |
|
106.00M |
|
$12.62 |
|
$12.23 |
|
| Balance Sheet Financials | |
$18.45B |
|
$5.46B |
|
$23.28B |
|
$41.73B |
|
$5.53B |
|
$1.99B |
|
$4.49B |
|
$10.02B |
|
$31.71B |
|
$30.40B |
|
$31.71B |
|
101.60M |
|
| Cash Flow Statement Financials | |
$1.89B |
|
$-521.60M |
|
$-2.03B |
|
$3.12B |
|
$2.47B |
|
$-657.70M |
|
$500.40M |
|
$-194.60M |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.34 |
|
-- |
|
-- |
|
0.06 |
|
0.09 |
|
86.56% |
|
30.15% |
|
30.15% |
|
-- |
|
35.61% |
|
30.23% |
|
$1.42B |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.19 |
|
0.65 |
|
137.71 |
|
4.09% |
|
4.27% |
|
3.11% |
|
3.85% |
|
$312.12 |
|
|
Free Cash Flow per Share |
$13.41 |
$17.85 |
|